GC Green Cross Wellbeing Signs Technology Transfer and Joint Development Agreement for Cancer Cachexia Treatment Candidate with Mtherapharma

Kim Sang-hyun, CEO of GC Green Cross Wellbeing (right), and Son Mi-won, CEO of M-Thera Pharma, are posing for a commemorative photo after signing a technology transfer and joint development agreement for 'GCWB204' at the GC Green Cross Wellbeing headquarters in Yeouido, Seoul, on the 14th.
[Photo by GC Green Cross Wellbeing]

[Asia Economy Reporter Lee Gwanju] GC Green Cross Wellbeing signed a technology transfer and joint development agreement on the 14th with Mthera Pharma for the cancer cachexia treatment candidate substance 'GCWB204'.

GC Green Cross Wellbeing will transfer research technologies including the substance, manufacturing method, and quality control of GCWB204, with a core technology of a fermentation process that can enhance special ginsenosides. Mthera Pharma plans to supplement the substance, manufacturing, and quality data of GCWB204 and conceive follow-up clinical trials with a new strategy.

Details of the contract will be kept confidential by mutual agreement of both companies, and royalties generated from the future development of the GCWB204 drug will be jointly distributed.

A GC Green Cross Wellbeing official said, "Through a strategic business agreement with Mthera Pharma, which has extensive experience in the manufacturing and quality control of natural medicine and clinical development, we will lay the foundation for GCWB204's entry into the global market."

An Mthera Pharma official stated, "We highly evaluated the overall trends and potential of GCWB204's marketability and clinical results for cancer patients, which led to this contract. We aim to successfully conduct clinical trials in the United States and accelerate global expansion in the future."

This content was produced with the assistance of AI translation services.